Back to top

Image: Bigstock

Why Earnings Season Could Be Great for Genmab (GNMSF)

Read MoreHide Full Article

Investors are always looking for stocks that are poised to beat at earnings season and Genmab A/S (GNMSF - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Genmab is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for GNMSF in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 57 cents per share for GNMSF, compared to a broader Zacks Consensus Estimate of 32 cents per share. This suggests that analysts have very recently bumped up their estimates for GNMSF, giving the stock a Zacks Earnings ESP of +80.95% heading into earnings season.

Genmab A/S Price and EPS Surprise

Genmab A/S Price and EPS Surprise

Genmab A/S price-eps-surprise | Genmab A/S Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that GNMSF has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Genmab, and that a beat might be in the cards for the upcoming report.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

See Latest Stocks Today >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Genmab A/S (GNMSF) - free report >>

More from Zacks Tale of the Tape

You May Like